Atea Pharmaceuticals (AVIR) Stock Forecast, Price Target & Predictions
AVIR Stock Forecast
Atea Pharmaceuticals stock forecast is as follows: an average price target of $6.88 (represents a 77.78% upside from AVIR’s last price of $3.87) and a rating consensus of 'Hold', based on 1 wall street analysts offering a 1-year stock forecast.
AVIR Price Target
The average price target for Atea Pharmaceuticals (AVIR) is $6.88 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $6.88 to $6.88. This represents a potential 77.78% upside from AVIR's last price of $3.87.
AVIR Analyst Ratings
According to 1 Wall Street analysts, Atea Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for AVIR stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Atea Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 12, 2024 | Matthew Harrison | Morgan Stanley | $6.88 | $3.35 | 105.37% | 77.78% |
The latest Atea Pharmaceuticals stock forecast, released on Aug 12, 2024 by Matthew Harrison from Morgan Stanley, set a price target of $6.88, which represents a 105.37% increase from the stock price at the time of the forecast ($3.35), and a 77.78% increase from AVIR last price ($3.87).
Atea Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $6.88 | $6.88 |
| Last Closing Price | $3.87 | $3.87 | $3.87 |
| Upside/Downside | -100.00% | 77.78% | 77.78% |
In the current month, the average price target of Atea Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Atea Pharmaceuticals's last price of $3.87. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 12, 2024 | Morgan Stanley | - | Equal-Weight | Upgrade |
Atea Pharmaceuticals's last stock rating was published by Morgan Stanley on Aug 12, 2024. The company Upgrade its AVIR rating from "null" to "Equal-Weight".
Atea Pharmaceuticals Financial Forecast
Atea Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $192.18M | $32.81M | $60.39M | $65.98M | $48.63M |
| Avg Forecast | $775.35M | $50.45M | $33.03M | $22.42M | $1.51M | - | - | - | - | - | - | - | - | $108.45M | $132.53M | $3.33M | $85.73M | $53.47M | $58.00M | $31.61M | $45.00M |
| High Forecast | $775.35M | $50.45M | $33.03M | $22.42M | $1.51M | - | - | - | - | - | - | - | - | $130.14M | $159.04M | $3.33M | $85.73M | $53.47M | $58.00M | $31.61M | $45.00M |
| Low Forecast | $775.35M | $50.45M | $33.03M | $22.42M | $1.51M | - | - | - | - | - | - | - | - | $86.76M | $106.02M | $3.33M | $85.73M | $53.47M | $58.00M | $31.61M | $45.00M |
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 9 | 7 | 3 | 2 | 17 | 14 | 6 | 7 | 12 | 7 | 7 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.24% | 0.61% | 1.04% | 2.09% | 1.08% |
Atea Pharmaceuticals's average Quarter revenue forecast for Mar 22 based on 6 analysts is $3.33M, with a low forecast of $3.33M, and a high forecast of $3.33M. AVIR's average Quarter revenue forecast represents a -98.27% decrease compared to the company's last Quarter revenue of $192.18M (Dec 21).
Atea Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 9 | 7 | 3 | 2 | 17 | 14 | 6 | 7 | 12 | 7 | 7 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-39.90M | $-16.18M | $-42.17M | $121.24M | $-22.09M | $8.75M | $30.72M | $20.66M |
| Avg Forecast | $491.17M | $31.96M | $20.92M | $14.20M | $954.66K | - | - | - | - | - | - | - | - | $68.70M | $-89.21M | $-47.26M | $54.31M | $-95.42M | $9.62M | $20.03M | $28.51M |
| High Forecast | $491.17M | $31.96M | $20.92M | $14.20M | $954.66K | - | - | - | - | - | - | - | - | $82.44M | $-71.37M | $-37.81M | $54.31M | $-76.33M | $11.55M | $20.03M | $28.51M |
| Low Forecast | $491.17M | $31.96M | $20.92M | $14.20M | $954.66K | - | - | - | - | - | - | - | - | $54.96M | $-107.06M | $-56.71M | $54.31M | $-114.50M | $7.70M | $20.03M | $28.51M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.58% | 0.18% | 0.89% | 2.23% | 0.23% | 0.91% | 1.53% | 0.72% |
6 analysts predict AVIR's average Quarter EBITDA for Mar 22 to be $-47.26M, with a high of $-37.81M and a low of $-56.71M. This is -138.98% lower than Atea Pharmaceuticals's previous annual EBITDA (Dec 21) of $121.24M.
Atea Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 9 | 7 | 3 | 2 | 17 | 14 | 6 | 7 | 12 | 7 | 7 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-34.43M | $-8.07M | $-41.98M | $117.13M | $-28.19M | $1.54M | $30.71M | $20.66M |
| Avg Forecast | $161.40M | $-21.12M | $-36.85M | $-47.25M | $-50.13M | $-47.18M | $-43.39M | $-42.13M | $-37.91M | $-36.51M | $-55.85M | $-43.72M | $-36.07M | $784.44M | $-113.88M | $-47.16M | $620.11M | $-121.80M | $1.69M | $243.25M | $20.44M |
| High Forecast | $161.40M | $-21.12M | $-36.85M | $-47.25M | $-50.13M | $-47.18M | $-43.39M | $-42.13M | $-37.91M | $-27.85M | $-55.85M | $-43.72M | $-22.95M | $941.33M | $-91.10M | $-37.72M | $744.13M | $-97.44M | $2.03M | $291.90M | $20.44M |
| Low Forecast | $161.40M | $-21.12M | $-36.85M | $-47.25M | $-50.13M | $-47.18M | $-43.39M | $-42.13M | $-37.91M | $-44.55M | $-55.85M | $-43.72M | $-42.63M | $627.55M | $-136.66M | $-56.59M | $496.09M | $-146.16M | $1.35M | $194.60M | $20.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.04% | 0.07% | 0.89% | 0.19% | 0.23% | 0.91% | 0.13% | 1.01% |
Atea Pharmaceuticals's average Quarter net income forecast for Mar 22 is $-47.16M, with a range of $-56.59M to $-37.72M. AVIR's average Quarter net income forecast represents a -140.26% decrease compared to the company's last Quarter net income of $117.13M (Dec 21).
Atea Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 9 | 7 | 3 | 2 | 17 | 14 | 6 | 7 | 12 | 7 | 7 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.36M | $11.38M | $12.54M | $13.19M | $11.94M | $11.90M | $8.76M | $14.14M |
| Avg Forecast | $554.42M | $36.07M | $23.62M | $16.03M | $1.08M | - | - | - | - | - | - | - | - | $88.31M | $48.22M | $2.38M | $69.81M | $51.58M | $13.09M | $22.60M | $32.18M |
| High Forecast | $554.42M | $36.07M | $23.62M | $16.03M | $1.08M | - | - | - | - | - | - | - | - | $105.97M | $57.87M | $2.38M | $83.77M | $61.89M | $15.71M | $22.60M | $32.18M |
| Low Forecast | $554.42M | $36.07M | $23.62M | $16.03M | $1.08M | - | - | - | - | - | - | - | - | $70.65M | $38.58M | $2.38M | $55.85M | $41.26M | $10.47M | $22.60M | $32.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.14% | 0.24% | 5.26% | 0.19% | 0.23% | 0.91% | 0.39% | 0.44% |
Atea Pharmaceuticals's average Quarter SG&A projection for Dec 23 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to AVIR last annual SG&A of $12.36M (Dec 22).
Atea Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 9 | 7 | 3 | 2 | 17 | 14 | 6 | 7 | 12 | 7 | 7 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.41 | $-0.10 | $-0.50 | $1.41 | $-0.34 | $0.02 | $0.37 | $0.25 |
| Avg Forecast | $1.92 | $-0.25 | $-0.44 | $-0.56 | $-0.59 | $-0.56 | $-0.52 | $-0.50 | $-0.45 | $-0.43 | $-0.66 | $-0.52 | $-0.43 | $-0.44 | $-0.41 | $-0.58 | $0.32 | $-0.05 | - | $-0.05 | $0.24 |
| High Forecast | $1.92 | $-0.25 | $-0.44 | $-0.56 | $-0.59 | $-0.56 | $-0.52 | $-0.50 | $-0.45 | $-0.33 | $-0.66 | $-0.52 | $-0.28 | $-0.44 | $-0.41 | $-0.58 | $0.32 | $-0.05 | - | $-0.05 | $0.24 |
| Low Forecast | $1.92 | $-0.25 | $-0.44 | $-0.56 | $-0.59 | $-0.56 | $-0.52 | $-0.50 | $-0.45 | $-0.53 | $-0.66 | $-0.52 | $-0.51 | $-0.44 | $-0.41 | $-0.58 | $0.32 | $-0.05 | - | $-0.05 | $0.24 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.24% | 0.86% | 4.34% | 6.47% | 4.46% | -6.83% | 1.02% |
According to 6 Wall Street analysts, Atea Pharmaceuticals's projected average Quarter EPS for Mar 22 is $-0.58, with a low estimate of $-0.58 and a high estimate of $-0.58. This represents a -141.31% decrease compared to AVIR previous annual EPS of $1.41 (Dec 21).
Atea Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| IMMX | Immix Biopharma | $1.86 | $7.00 | 276.34% | Buy |
| CNSP | CNS Pharmaceuticals | $0.15 | $0.50 | 233.33% | - |
| AVIR | Atea Pharmaceuticals | $3.87 | $6.88 | 77.78% | Hold |
AVIR Forecast FAQ
Is Atea Pharmaceuticals a good buy?
No, according to 1 Wall Street analysts, Atea Pharmaceuticals (AVIR) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of AVIR's total ratings.
What is AVIR's price target?
Atea Pharmaceuticals (AVIR) average price target is $6.88 with a range of $6.88 to $6.88, implying a 77.78% from its last price of $3.87. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Atea Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for AVIR stock, the company can go up by 77.78% (from the last price of $3.87 to the average price target of $6.88), up by 77.78% based on the highest stock price target, and up by 77.78% based on the lowest stock price target.
Can Atea Pharmaceuticals stock reach $6?
AVIR's average twelve months analyst stock price target of $6.88 supports the claim that Atea Pharmaceuticals can reach $6 in the near future.
What are Atea Pharmaceuticals's analysts' financial forecasts?
Atea Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.51M (high $1.51M, low $1.51M), average EBITDA is $954.66K (high $954.66K, low $954.66K), average net income is $-183M (high $-183M, low $-183M), average SG&A $1.08M (high $1.08M, low $1.08M), and average EPS is $-2.17 (high $-2.17, low $-2.17). AVIR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $881.25M (high $881.25M, low $881.25M), average EBITDA is $558.26M (high $558.26M, low $558.26M), average net income is $56.18M (high $56.18M, low $56.18M), average SG&A $630.14M (high $630.14M, low $630.14M), and average EPS is $0.667 (high $0.667, low $0.667).
Did the AVIR's actual financial results beat the analysts' financial forecasts?
Based on Atea Pharmaceuticals's last annual report (Dec 2021), the company's revenue was $351.37M, beating the average analysts forecast of $228.8M by 53.57%. Apple's EBITDA was $138.38M, missing the average prediction of $-11.462M by -1307.22%. The company's net income was $121.19M, missing the average estimation of $743.25M by -83.69%. Apple's SG&A was $45.78M, missing the average forecast of $157.08M by -70.85%. Lastly, the company's EPS was $1.46, beating the average prediction of $0.223 by 555.81%. In terms of the last quarterly report (Dec 2021), Atea Pharmaceuticals's revenue was $192.18M, beating the average analysts' forecast of $85.73M by 124.18%. The company's EBITDA was $121.24M, beating the average prediction of $54.31M by 123.25%. Atea Pharmaceuticals's net income was $117.13M, missing the average estimation of $620.11M by -81.11%. The company's SG&A was $13.19M, missing the average forecast of $69.81M by -81.11%. Lastly, the company's EPS was $1.41, beating the average prediction of $0.325 by 334.01%